# The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

> **NCT03178669** · PHASE2 · COMPLETED · sponsor: **InDex Pharmaceuticals** · enrollment: 213 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** cobitolimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03178669
- **Lead sponsor:** InDex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-08-30
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178669, "The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03178669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*